NPM1
Invivoscribe, Kronos Bio Partner on Companion Diagnostic Test for Leukemia Drug
The companion diagnostic assay would identify mutations in the NPM1 gene, which Kronos Bio is targeting with its investigational drug entospletinib.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.
Dana-Farber, Brigham and Women's Develop NGS Panel for Rapid Diagnosis of Hematologic Cancers
Premium
The 95-gene test is for detecting leukemia, myelodysplastic syndromes, and myeloproliferative disorders and can return results in less than one week.
Trovagene announced last month that it has granted Novartis' diagnostics laboratory, Genoptix, a worldwide, non-exclusive license to incorporate the nucleophosmin protein marker into research and clinical testing services for acute myelogenous leukemia.